SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunicum - ilixadencel in MERECA Phase II - results soon !
An SI Board Since July 2019
Posts SubjectMarks Bans Symbol
16 1 0 IMMU.ST
Emcee:  loparn Type:  Moderated
Swedish biotech company Immunicum has begun to rally before the MERECA Phase II metastatic RCC study results which will be presented in the first week of September this year. But the stock is still very cheap in my view with respect to its risk/reward. tinyurl.com

My thorough analysis of Immunicum's MERECA study outlook automatically translated to English from the Swedish original seems readable even without to much editing :
infoom.se

It explains why for examle I have a big share of Immunicum in my portfolio and look forward to the results of MERECA in the first week of September. There is also a link to a Immunicum presentation for those who want to learn more how ilixadencel is positioned in the cancer immunotherapy landscape as a so called primer (of tumorspecific CD8+ cytotoxic T-cells) with enormous potential in all injectable solid tumors.
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
16Here is an anonymous person's statistical model simulation of the MERECA stuloparn-February 14
15Edison increases the valuation of Immunicum. "Immunicum’s updated results loparn-February 7
14Newsrelease today : "Immunicum AB (publ) Presents Updated Data from Phase loparn-February 6
13Immunicum's new abstract satisfies the stock market today. finance.yahoo.comloparn-February 4
12"Immunicum AB (publ; IMMU.ST) announced today that the abstract covering daloparn-12/20/2019
11"Immunicum AB (publ) Announces Positive Preclinical Data on Ilixadencel in loparn-10/21/2019
10Immmunicum : A shorter-induced short-squeeze hopefully may have started in the Iloparn-10/4/2019
9Immunicum has presented a pdf with the complete MERECA result analysis. immunicloparn-9/26/2019
8A link that functions youtube.comloparn-9/25/2019
7Immunicum CEO presented the MERECA results in a video today. There you can see eloparn-9/25/2019
6[tweet]SI Ron (Soup Nazi)-9/25/2019
5Immunicum "takes revenge" with very good data from MERECA according toloparn-9/25/2019
4Immunicum CEO, Carlos de Sousa, explains the details behind the top-line Phase Iloparn-9/5/2019
3"Immunicum AB (publ) Announces Positive Phase II MERECA Topline Results Incloparn-8/29/2019
2Immunicum held a very informative company presentation in Stockholm today, mostlloparn-8/20/2019
1A new Immunicum presentation : immunicum.seloparn-8/9/2019
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):